Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 4.29 2.63% 0.11
CRVS closed up 2.63 percent on Monday, March 18, 2019, on 1.43 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical CRVS trend table...

Date Alert Name Type % Chg
Mar 18 20 DMA Resistance Bearish 0.00%
Mar 18 Crossed Above 50 DMA Bullish 0.00%
Mar 18 Stochastic Buy Signal Bullish 0.00%
Mar 18 NR7 Range Contraction 0.00%
Mar 18 Inside Day Range Contraction 0.00%
Mar 18 Oversold Stochastic Weakness 0.00%
Mar 15 20 DMA Resistance Bearish 2.63%
Mar 15 50 DMA Resistance Bearish 2.63%
Mar 15 Oversold Stochastic Weakness 2.63%
Mar 14 Fell Below 50 DMA Bearish 1.90%

Older signals for CRVS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Biotechnology Biopharmaceutical Medical Specialties Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Immune Checkpoint Oncology Therapies
Is CRVS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.91
52 Week Low 3.22
Average Volume 103,323
200-Day Moving Average 7.7655
50-Day Moving Average 4.2378
20-Day Moving Average 4.371
10-Day Moving Average 4.283
Average True Range 0.3465
ADX 14.39
+DI 16.7625
-DI 17.6365
Chandelier Exit (Long, 3 ATRs ) 4.4005
Chandelier Exit (Short, 3 ATRs ) 4.9295
Upper Bollinger Band 4.9307
Lower Bollinger Band 3.8113
Percent B (%b) 0.43
BandWidth 25.6097
MACD Line -0.0166
MACD Signal Line 0.0156
MACD Histogram -0.0322
Fundamentals Value
Market Cap 89.81 Million
Num Shares 20.9 Million
EPS -2.58
Price-to-Earnings (P/E) Ratio -1.66
Price-to-Sales 0.00
Price-to-Book 2.78
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.65
Resistance 3 (R3) 4.65 4.52 4.59
Resistance 2 (R2) 4.52 4.43 4.53 4.57
Resistance 1 (R1) 4.41 4.38 4.47 4.41 4.55
Pivot Point 4.28 4.28 4.31 4.29 4.28
Support 1 (S1) 4.17 4.19 4.23 4.17 4.03
Support 2 (S2) 4.04 4.14 4.05 4.01
Support 3 (S3) 3.93 4.04 3.99
Support 4 (S4) 3.93